The German biotech company CureVac, which became famous because of its coronavirus vaccine candidate, can, as hoped, raise well more than 200 million US dollars from investors in the course of its IPO. The initially slightly more than 13.3 million shares would be placed at $ 16 each, the company announced today.
The subscribers for the shares could also order up to almost two million additional papers at short notice. A total of around 245 million dollars (207 million euros) would then flow into the company. The trading of the papers will start on the US tech exchange NASDAQ.
Around $ 150 million of the proceeds are said to flow into the development of a coronavirus vaccine. According to the prospectus, the short-term production capacity will be expanded with a further 50 million dollars. In the search for a vaccine against SARS-CoV-2, CureVac is one of several hopes worldwide.
–
–
